公开(公告)号：US20110223870A1

公开(公告)日：2011-09-15

申请号：US12815540

申请日：2010-06-15

申请人： Djordje Tujkovic ,  Vummintala Shashidhar ,  Erik Stauffer ,  Rishi Ranjan ,  Soumen Chakraborty ,  Bertrand Hochwald ,  Sriram Rajagopal ,  Sam Alex

发明人： Djordje Tujkovic ,  Vummintala Shashidhar ,  Erik Stauffer ,  Rishi Ranjan ,  Soumen Chakraborty ,  Bertrand Hochwald ,  Sriram Rajagopal ,  Sam Alex

IPC分类号： H04B7/02 ,  H04B1/38

CPC分类号： H04B7/0671 ,  H04B7/0691

摘要： Methods and apparatus of allocating antennas for cyclic delay diversity (CDD) transmission are disclosed. One method includes estimating a transmission channel of a transceiver having a plurality of antennas. A subset of a plurality of transceiver antennas is selected based on the estimated transmission channel. A single transceiver antenna of the subset is identified based on a channel quality of a transmission path of the single transceiver antenna. Cyclic delay diversity (CDD) signals are transmitted from the subset of the plurality of antennas, wherein a minimally delayed CDD signal is transmitted from the identified single transceiver antenna of the subset of the plurality of transceiver antennas.

摘要翻译： 公开了分配用于循环延迟分集（CDD）传输的天线的方法和装置。 一种方法包括估计具有多个天线的收发机的传输信道。 基于估计的传输信道来选择多个收发天线的子集。 基于单个收发器天线的传输路径的信道质量来识别该子集的单个收发天线。 从多个天线的子集中发送循环延迟分集（CDD）信号，其中从所述多个收发器天线的子集的所识别的单个收发器天线发送最小延迟的CDD信号。

公开(公告)号：US20110212943A1

公开(公告)日：2011-09-01

申请号：US13123983

申请日：2009-10-14

申请人： Gopalan Balasubramanian ,  Ponpandian Thanasekaran ,  Sridharan Rajagopal ,  Bharathimohan Kuppusamy ,  Virendra Kachhadia ,  Vignesh Radhakrishnan ,  Sivasudar Velaiah ,  Shridhar Narayanan ,  Mandar Bhonde ,  Praveen Rajendran ,  Sriram Rajagopal

发明人： Gopalan Balasubramanian ,  Ponpandian Thanasekaran ,  Sridharan Rajagopal ,  Bharathimohan Kuppusamy ,  Virendra Kachhadia ,  Vignesh Radhakrishnan ,  Sivasudar Velaiah ,  Shridhar Narayanan ,  Mandar Bhonde ,  Praveen Rajendran ,  Sriram Rajagopal

IPC分类号： A61K31/165 ,  C07C237/20 ,  C07D223/14 ,  C07C237/22 ,  C07D207/337 ,  C07D307/54 ,  C07C231/02 ,  C07C229/46 ,  A61K31/55 ,  A61K31/40 ,  A61K31/341 ,  C12N9/99 ,  A61P29/00 ,  A61P19/02 ,  A61P31/00 ,  A61P1/00 ,  A61P25/28 ,  A61P35/00 ,  A61P35/04

CPC分类号： C07C259/06 ,  C07C237/20 ,  C07C237/42 ,  C07C271/22 ,  C07C2603/74 ,  C07D207/337 ,  C07D471/18

摘要： Provided herein are novel bridged cyclic derivatives of the general formula (I), their analogs, tautomeric forms, stereoisomers, polymorphs, solvates, intermediates, pharmaceutically acceptable salts, pharmaceutical compositions, metabolites and prodrugs thereof. These compounds can inhibit HDACs and are useful as therapeutic or ameliorating agent for diseases that are involved in cellular growth such as malignant tumors, autoimmune diseases, skin diseases, infections, inflammation, neurode-generative disorders etc.

摘要翻译： 本文提供了通式（I）的新型桥连环衍生物，其类似物，互变异构形式，立体异构体，多晶型物，溶剂化物，中间体，药学上可接受的盐，药物组合物，代谢物和前药。 这些化合物可以抑制HDAC，并且可用作涉及细胞生长的疾病如恶性肿瘤，自身免疫疾病，皮肤疾病，感染，炎症，神经发生障碍等的治疗或改善剂。

公开(公告)号：US20100291003A1

公开(公告)日：2010-11-18

申请号：US12734030

申请日：2008-10-21

申请人： Sridharan Rajagopal ,  Virendra Kachhadia ,  Thanasekaran Ponpandian ,  Abdul Raheem Keeri ,  Karnambaram Anandhan ,  Sriram Rajagopal ,  Rajendran Praveen ,  Prabhu Daivasigamani

发明人： Sridharan Rajagopal ,  Virendra Kachhadia ,  Thanasekaran Ponpandian ,  Abdul Raheem Keeri ,  Karnambaram Anandhan ,  Sriram Rajagopal ,  Rajendran Praveen ,  Prabhu Daivasigamani

IPC分类号： A61K9/12 ,  C12N5/02 ,  A61K31/54 ,  A61K31/535 ,  A61K31/36 ,  A61K31/16 ,  C07D279/12 ,  C07D295/18 ,  C07D317/44 ,  C07C233/00 ,  A61P35/04

CPC分类号： C07C259/06 ,  C07C233/44 ,  C07C237/38 ,  C07C237/40 ,  C07C259/10 ,  C07C2601/02 ,  C07C2601/08 ,  C07C2601/18 ,  C07D209/18 ,  C07D213/56 ,  C07D295/185 ,  C07D317/60 ,  C07D333/24

摘要： Novel compounds of the general formula (I), having histone deacetylase (HDAC) inhibiting enzymatic activity, their derivatives, analogs, tautomeric forms, stereoisomers, polymorphs, hydrates, solvates, intermediates, pharmaceutically acceptable salts, pharmaceutical compositions, metabolites and prodrugs thereof. The present invention more particularly provides novel compounds of the general formula (I). Also included is a method for treatment of cancer, psoriasis, proliferative conditions and conditions mediated by HDAC, in a mammal comprising administering an effective amount of a novel compound of formula (I).

摘要翻译： 具有抑制酶活性的组蛋白脱乙酰酶（HDAC），其衍生物，类似物，互变异构形式，立体异构体，多晶型物，水合物，溶剂合物，中间体，药学上可接受的盐，药物组合物，代谢物和前药的通式（I）的新型化合物。 本发明更具体地提供了通式（I）的新型化合物。 还包括在哺乳动物中治疗癌症，牛皮癣，增殖性病症和由HDAC介导的病症的方法，包括施用有效量的新的式（I）化合物。

公开(公告)号：US20090093423A2

公开(公告)日：2009-04-09

申请号：US11822956

申请日：2007-07-11

申请人： Senthilkumar UDAYAMPALAYAMPALANISAMY ,  Andrew GNANAPRAKASAM ,  Panchapakesan GANAPATHY ,  Mukut GOHAIN ,  Venkatasubramanian HARIHARAN ,  Sriram RAJAGOPAL ,  Maneesh PAUL-SATYASEELA ,  Shakti SINGH SOLANKI ,  Sathishkumar DEVARAJAN

发明人： Senthilkumar UDAYAMPALAYAMPALANISAMY ,  Andrew GNANAPRAKASAM ,  Panchapakesan GANAPATHY ,  Mukut GOHAIN ,  Venkatasubramanian HARIHARAN ,  Sriram RAJAGOPAL ,  Maneesh PAUL-SATYASEELA ,  Shakti SINGH SOLANKI ,  Sathishkumar DEVARAJAN

IPC分类号： A61K31/431 ,  A61K31/7036 ,  A61P31/00 ,  C07D499/00

CPC分类号： C07D499/86 ,  Y02P20/55

摘要： Novel 2-substituted methyl penam derivatives include the formula (I), their analogs, their tautomeric forms, their stereoisomers, their polymorphs, their solvates, their pharmaceutically acceptable salts, and pharmaceutical compositions containing them; wherein A=C or N; Het is a three- to seven-membered heterocyclic ring; R1 represents carboxylate anion, or —COOR4 where R4 represents hydrogen, carboxylic acid protecting group or a pharmaceutically acceptable salt; R2 and R3 may be same or different and independently represent hydrogen, halogen, amino, alkyl, protected amino, optionally substituted alkyl, alkenyl, alkynyl and the like; R represents substituted or unsubstituted alkyl, alkenyl, aryl, aralkyl, cycloalkyl, heterocyclyl or heterocyclylalkyl.

摘要翻译： 新的2-取代的甲基penam衍生物包括式（I），它们的类似物，它们的互变异构形式，它们的立体异构体，它们的多晶型物，它们的溶剂合物，其药学上可接受的盐和含有它们的药物组合物; 其中A = C或N; Het是一个三至七元的杂环; R1表示羧酸根阴离子，或-COOR4，其中R4表示氢，羧酸保护基或药学上可接受的盐; R2和R3可以相同或不同，并且独立地表示氢，卤素，氨基，烷基，保护的氨基，任选取代的烷基，烯基，炔基等; R代表取代或未取代的烷基，烯基，芳基，芳烷基，环烷基，杂环基或杂环基烷基。

公开(公告)号：US20080207606A1

公开(公告)日：2008-08-28

申请号：US12068668

申请日：2008-02-08

申请人： Akella Satya Surya Visweswara Srinivas ,  Ravikumar Tadiparthi ,  Ganapavarapu Veera Raghava Sharma ,  Sappanimuthu Thirunavukkarasu ,  Durairaj Peter Bhakiaraj ,  Virendra Kachhadia ,  Kilambi Narsimhan ,  Sathya Narayana Thara ,  Sriram Rajagopal ,  Gaddam Om Reddy ,  Sukunath Narayanan ,  Venkatesan Parameswaran ,  Venkatesan Janarthanam ,  Maruthikumar Narayanam ,  Sathyanarayana Gadde ,  Uma Ramachandran

发明人： Akella Satya Surya Visweswara Srinivas ,  Ravikumar Tadiparthi ,  Ganapavarapu Veera Raghava Sharma ,  Sappanimuthu Thirunavukkarasu ,  Durairaj Peter Bhakiaraj ,  Virendra Kachhadia ,  Kilambi Narsimhan ,  Sathya Narayana Thara ,  Sriram Rajagopal ,  Gaddam Om Reddy ,  Sukunath Narayanan ,  Venkatesan Parameswaran ,  Venkatesan Janarthanam ,  Maruthikumar Narayanam ,  Sathyanarayana Gadde ,  Uma Ramachandran

IPC分类号： A61K31/541 ,  C07D239/24 ,  A61K31/505 ,  A61K31/496 ,  A61P37/00 ,  A61P35/00 ,  A61P19/02 ,  A61P29/00 ,  C07D295/00 ,  A61K31/5377

CPC分类号： C07D213/30 ,  C07D239/30 ,  C07D239/32 ,  C07D239/34 ,  C07D239/42 ,  C07D239/52 ,  C07D401/04 ,  C07D401/12 ,  C07D403/04 ,  C07D403/12 ,  C07D403/14 ,  C07D405/12 ,  C07D405/14 ,  C07D409/12 ,  C07D409/14 ,  C07D413/04 ,  C07D417/04 ,  C07D417/12 ,  C07D417/14

摘要： Novel heterocyclic compounds of the general formula (I), their derivatives, analogs, tautomeric forms, stereoisomers, polymorphs, hydrates, solvates, pharmaceutically acceptable salts, pharmaceutical compositions, metabolites and prodrugs thereof are described. These compounds are useful in the treatment of immunological diseases, inflammation, pain disorder, rheumatoid arthritis; osteoporosis; multiple myeloma; uveititis; acute and chronic myelogenous leukemia; atherosclerosis; cancer; cachexia; ischemic-induced cell-damage; pancreatic beta cell destruction; osteoarthritis; rheumatoid spondylitis; gouty arthritis; inflammatory bowel disease; adult respiratory distress syndrome (ARDS); psoriasis; Crohn's disease; allergic rhinitis; ulcerative colitis; anaphylaxis; contact dermatitis; muscle degeneration; asthma; COPD; bone resorption diseases; multiple sclerosis; sepsis; septic shock; toxic shock syndrome and fever. More particularly these compounds are useful as PDE4 inhibitors, and useful for treating PDE4 mediated diseases.

摘要翻译： 描述了通式（I）的新型杂环化合物，其衍生物，类似物，互变异构形式，立体异构体，多晶型物，水合物，溶剂合物，药学上可接受的盐，药物组合物，代谢物和前药。 这些化合物可用于治疗免疫疾病，炎症，疼痛障碍，类风湿性关节炎; 骨质疏松症 多发性骨髓瘤 葡萄膜炎 急性和慢性粒细胞白血病; 动脉粥样硬化 癌症; 恶病质 缺血诱导的细胞损伤; 胰腺β细胞破坏; 骨关节炎 类风湿性脊柱炎; 痛风性关节炎 炎症性肠病; 成人呼吸窘迫综合征（ARDS）; 银屑病; 克罗恩病; 过敏性鼻炎; 溃疡性结肠炎 过敏反应 接触性皮炎; 肌肉退化; 哮喘; COPD; 骨吸收疾病; 多发性硬化症 败血症 败血性休克 中毒性休克综合征和发烧。 更特别地，这些化合物可用作PDE4抑制剂，并且可用于治疗PDE4介导的疾病。

公开(公告)号：US20070111998A1

公开(公告)日：2007-05-17

申请号：US11546299

申请日：2006-10-12

申请人： Siripragada Rao ,  Akella Satya Srinivas ,  Shikha Rani ,  Gaddam Reddy ,  Sriram Rajagopal ,  Uma Ramachandran ,  Duddu Sharada ,  Rajagopalan Nirmala ,  Velaiah Sivasudar ,  Lakshmanan Manikandan ,  Ramachandran Balaji

发明人： Siripragada Rao ,  Akella Satya Srinivas ,  Shikha Rani ,  Gaddam Reddy ,  Sriram Rajagopal ,  Uma Ramachandran ,  Duddu Sharada ,  Rajagopalan Nirmala ,  Velaiah Sivasudar ,  Lakshmanan Manikandan ,  Ramachandran Balaji

IPC分类号： A61K31/541 ,  A61K31/5377 ,  A61K31/496 ,  A61K31/454 ,  A61K31/4439 ,  A61K31/427 ,  A61K31/416 ,  A61K31/403 ,  C07D417/02 ,  C07D403/02 ,  C07D413/02

CPC分类号： C07D209/88 ,  C07D401/12 ,  C07D401/14 ,  C07D403/12 ,  C07D405/12 ,  C07D405/14 ,  C07D409/12 ,  C07D417/12

摘要： The present invention relates to novel heterocyclic compounds of the general formula (I), as IL-6 inhibitors, their derivatives, their analogs, their tautomeric forms, their stereoisomers, their polymorphs, their hydrates, their solvates, their pharmaceutically acceptable salts and compositions, their metabolites and prodrugs thereof. The present invention more particularly provides novel heterocyclic compounds of the general formula (I). Also included is a method for treatment of cancer, cancer cachexia and inflammatory diseases including immunological diseases, particularly those mediated by cytokines such as IL-6, through pSTAT3 inhibition, in a mammal comprising administering an effective amount of a compound of formula (I) as described above.

摘要翻译： 本发明涉及通式（I）的新型杂环化合物，作为IL-6抑制剂，其衍生物，其类似物，其互变异构形式，其立体异构体，其多晶型物，其水合物，其溶剂合物，其药学上可接受的盐和组合物 ，它们的代谢物和前药。 本发明更具体地提供了通式（I）的新型杂环化合物。 还包括在哺乳动物中治疗癌症，癌症恶病质和炎性疾病的方法，包括免疫疾病，特别是通过pSTAT3抑制的细胞因子如IL-6介导的疾病，包括给予有效量的式（I）化合物， 如上所述。

公开(公告)号：US06486196B2

公开(公告)日：2002-11-26

申请号：US09849586

申请日：2001-05-04

申请人： Srinivas Nanduri ,  Sairam Pothukuchi ,  Sriram Rajagopal ,  Venkateswarlu Akella ,  Sunilkumar Bhadramma Kochunarayana Pillai ,  Ranjan Chakrabarti

发明人： Srinivas Nanduri ,  Sairam Pothukuchi ,  Sriram Rajagopal ,  Venkateswarlu Akella ,  Sunilkumar Bhadramma Kochunarayana Pillai ,  Ranjan Chakrabarti

IPC分类号： A61K31335

CPC分类号： C07D407/06 ,  C07D307/34

摘要： The present invention relates to novel anticancer agents, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts, and their pharmaceutically acceptable solvates. The present invention more particularly relates to novel derivatives of andrographolide, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts, and their pharmaceutically acceptable solvates. The novel derivatives of andrographolide have the general formula (I).

摘要翻译： 本发明涉及新型抗癌剂，其立体异构体，其多晶型物，其药学上可接受的盐及其药学上可接受的溶剂合物。 本发明更具体地涉及穿心莲内酯的新型衍生物，其立体异构体，其多晶型物，其药学上可接受的盐及其药学上可接受的溶剂合物。 穿心莲内酯的新衍生物具有通式（I）。

公开(公告)号：US06410590B1

公开(公告)日：2002-06-25

申请号：US09775533

申请日：2001-02-01

申请人： Srinivas Nanduri ,  Sriram Rajagopal ,  Sairam Pothukuchi ,  Sunilkumar Bhadramma Kochunarayana Pillai ,  Ranjan Chakrabarti

发明人： Srinivas Nanduri ,  Sriram Rajagopal ,  Sairam Pothukuchi ,  Sunilkumar Bhadramma Kochunarayana Pillai ,  Ranjan Chakrabarti

IPC分类号： A61K31341

CPC分类号： C07D407/06

摘要： The present invention relates to novel derivatives of Andrographolide, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts, and their pharmaceutically acceptable solvates. The novel derivatives of Andrographolide have the general formula (I) The andrographolide derivatives represented by general formula (I) are useful for treating cancer, HSV, HIV, psoriasis, restonosis, atherosclerosis, other cardiovascular disorders, and can be used as antiviral, antimalarial, antibacterial, hepatoprotective, and immunomodulating agents and for treatment of other metabolic disorders.

摘要翻译： 本发明涉及穿心莲内酯的新衍生物，其立体异构体，其多晶型物，其药学上可接受的盐及其药学上可接受的溶剂合物。 穿心莲内酯的新型衍生物具有通式（I）由通式（I）表示的穿心莲内酯衍生物可用于治疗癌症，HSV，HIV，牛皮癣，再狭窄，动脉粥样硬化，其他心血管疾病，可用作抗病毒，抗疟药 ，抗菌，肝保护和免疫调节剂和治疗其他代谢紊乱。

公开(公告)号：US08450525B2

公开(公告)日：2013-05-28

申请号：US12734030

申请日：2008-10-21

申请人： Sridharan Rajagopal ,  Virendra Kachhadia ,  Thanasekaran Ponpandian ,  Abdul Raheem Keeri ,  Karnambaram Anandhan ,  Sriram Rajagopal ,  Rajendran Praveen ,  Prabhu Daivasigamani

发明人： Sridharan Rajagopal ,  Virendra Kachhadia ,  Thanasekaran Ponpandian ,  Abdul Raheem Keeri ,  Karnambaram Anandhan ,  Sriram Rajagopal ,  Rajendran Praveen ,  Prabhu Daivasigamani

IPC分类号： C07C233/65 ,  A61K31/16

CPC分类号： C07C259/06 ,  C07C233/44 ,  C07C237/38 ,  C07C237/40 ,  C07C259/10 ,  C07C2601/02 ,  C07C2601/08 ,  C07C2601/18 ,  C07D209/18 ,  C07D213/56 ,  C07D295/185 ,  C07D317/60 ,  C07D333/24

摘要： Novel compounds of the general formula (I), having histone deacetylase (HDAC) inhibiting enzymatic activity, their derivatives, analogs, tautomeric forms, stereoisomers, polymorphs, hydrates, solvates, intermediates, pharmaceutically acceptable salts, pharmaceutical compositions, metabolites and prodrugs thereof. The present invention more particularly provides novel compounds of the general formula (I). Also included is a method for treatment of cancer, psoriasis, proliferative conditions and conditions mediated by HDAC, in a mammal comprising administering an effective amount of a novel compound of formula (I).

摘要翻译： 具有抑制酶活性的组蛋白脱乙酰酶（HDAC），其衍生物，类似物，互变异构形式，立体异构体，多晶型物，水合物，溶剂合物，中间体，药学上可接受的盐，药物组合物，代谢物和前药的通式（I）的新型化合物。 本发明更具体地提供了通式（I）的新型化合物。 还包括在哺乳动物中治疗癌症，牛皮癣，增殖性病症和由HDAC介导的病症的方法，包括施用有效量的新的式（I）化合物。

公开(公告)号：US20130130751A1

公开(公告)日：2013-05-23

申请号：US13309290

申请日：2011-12-01

申请人： Shashidhar Vummintala ,  Gowrisankar Somichetty ,  Sriram Rajagopal ,  Sindhu Verma ,  Manish Airy ,  Hariprasad Gangadharan ,  Pugazhanthi R.P. ,  Felix Varghese ,  Erik Stauffer

发明人： Shashidhar Vummintala ,  Gowrisankar Somichetty ,  Sriram Rajagopal ,  Sindhu Verma ,  Manish Airy ,  Hariprasad Gangadharan ,  Pugazhanthi R.P. ,  Felix Varghese ,  Erik Stauffer

IPC分类号： H04W52/02

CPC分类号： H04W52/0216 ,  H03D7/16 ,  H04L41/0803 ,  H04W28/0263 ,  Y02D70/00 ,  Y02D70/1262 ,  Y02D70/146 ,  Y02D70/164 ,  Y02D70/23 ,  Y02D70/24

摘要： A wireless communication device is disclosed that is capable of reduced power consumption. Uplink and downlink sub-frames in a WiMAX, 802.16m or LTE environment often include several vacant symbols during which power-hungry hardware and software components need not operate at full power. By analyzing a physical layer beacon and control information of a received signal, the specific locations of data bursts can be determined, as well as periods of needed operation of a receiver module to effectively decode those data bursts. The receiver module can otherwise be controlled to operate in a LOW power state during remaining periods of vacant time, thereby conserving power consumption and extending battery life.

摘要翻译： 公开了能够降低功耗的无线通信设备。 WiMAX，802.16m或LTE环境中的上行链路和下行链路子帧通常包括几个空闲符号，在此期间，功耗很大的硬件和软件组件不需要在全功率下运行。 通过分析接收信号的物理层信标和控制信息，可以确定数据突发的特定位置以及接收机模块有效解码这些数据脉冲串的所需操作周期。 否则，在空闲时间的剩余时间期间，接收器模块可以被控制为在低功率状态下操作，从而节省功耗并延长电池寿命。